We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) closed the most recent trading day at $9.16, moving +2.35% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.72%. Elsewhere, the Dow gained 0.3%, while the tech-heavy Nasdaq added 1.12%.
Heading into today, shares of the infectious disease drug developer had gained 12.3% over the past month, lagging the Medical sector's gain of 12.48% and outpacing the S&P 500's loss of 0.9%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. In that report, analysts expect Adma Biologics to post earnings of $0.16 per share. This would mark year-over-year growth of 6.67%. Meanwhile, our latest consensus estimate is calling for revenue of $125.77 million, up 3.11% from the prior-year quarter.
ADMA's full-year Zacks Consensus Estimates are calling for earnings of $0.82 per share and revenue of $535 million. These results would represent year-over-year changes of +36.67% and +4.87%, respectively.
Investors should also note any recent changes to analyst estimates for Adma Biologics. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 2.38% lower. Adma Biologics is holding a Zacks Rank of #5 (Strong Sell) right now.
Looking at its valuation, Adma Biologics is holding a Forward P/E ratio of 10.91. This expresses a discount compared to the average Forward P/E of 21.56 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 150, putting it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Adma Biologics (ADMA - Free Report) closed the most recent trading day at $9.16, moving +2.35% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.72%. Elsewhere, the Dow gained 0.3%, while the tech-heavy Nasdaq added 1.12%.
Heading into today, shares of the infectious disease drug developer had gained 12.3% over the past month, lagging the Medical sector's gain of 12.48% and outpacing the S&P 500's loss of 0.9%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. In that report, analysts expect Adma Biologics to post earnings of $0.16 per share. This would mark year-over-year growth of 6.67%. Meanwhile, our latest consensus estimate is calling for revenue of $125.77 million, up 3.11% from the prior-year quarter.
ADMA's full-year Zacks Consensus Estimates are calling for earnings of $0.82 per share and revenue of $535 million. These results would represent year-over-year changes of +36.67% and +4.87%, respectively.
Investors should also note any recent changes to analyst estimates for Adma Biologics. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 2.38% lower. Adma Biologics is holding a Zacks Rank of #5 (Strong Sell) right now.
Looking at its valuation, Adma Biologics is holding a Forward P/E ratio of 10.91. This expresses a discount compared to the average Forward P/E of 21.56 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 150, putting it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.